JP7179452B2 - O/W/O type emulsion composition - Google Patents

Description

The present invention relates to an O/W/O emulsion composition, and more particularly to an O/W/O emulsion composition containing (a) hydrogenated lecithin and (b) diglyceryl monooleate.

O/W/O emulsion compositions are also called oil-in-water emulsion compositions, O/W/O composite emulsions, multiple emulsions, etc., and are important in various industrial applications such as cosmetics, foods, and pharmaceuticals. It's becoming An O/W/O emulsion composition has a characteristic structure in which an aqueous phase is dispersed in an outer oil phase, and an inner oil phase is further dispersed in the aqueous phase. For this reason, it is known to have the advantage of being able to provide a special feeling of use (spreadability at the time of application, compatibility with the skin) that cannot be obtained with a simple O/W emulsion composition or a W/O emulsion composition. (Patent Documents 1 and 2).

On the other hand, by including (a) hydrogenated lecithin and (b) diglyceryl monooleate in the O/W/O emulsion composition, the permeability of the stratum corneum of the drug contained in the composition is improved. . No technical reports have been confirmed.

JP-A-9-151126 JP-A-11-76799

Conventional O/W/O emulsion compositions such as those described in Patent Documents 1 and 2 have succeeded in solving the problems related to feeling during use and stability over time, but the drug contained in the composition improve stratum corneum penetration. However, there were still issues regarding effectiveness.

The present invention is intended to solve the above-mentioned problems, and improves the stratum corneum penetration of the drug contained in the O/W/O emulsion composition, and achieves both penetration feeling and stability over time. The objective is to provide a technology that allows

In view of this situation, the present inventors have found that the O/W/O emulsified composition contains (a) hydrogenated lecithin and (b) diglyceryl monooleate. The inventors have found that it is possible to improve the permeability of the stratum corneum of the currently used drug, and that it is compatible with the feeling of penetration and stability over time, and have completed the present invention. That is, the present invention is as shown below.
<1> An O/W/O emulsion composition containing (a) hydrogenated lecithin and (b) diglyceryl monooleate.
<2><1>, wherein (a) hydrogenated lecithin and (b) diglyceryl monooleate are contained in a range of (a):(b) = 19:1 to 12:8. <3><1> or <2, wherein (a) hydrogenated lecithin and (b) diglyceryl monooleate are present at the interface of the O/W emulsion <4> Any one of <1> to <3>, wherein the ratio of the O/W emulsion in the composition is 65 to 80% by weight. <5> The O/W/O emulsion composition according to any one of <1> to <4>, wherein the proportion of the internal oil phase in the composition is 2 to 20% by weight. O/W/O emulsion composition <6> O/W according to any one of <1> to <5>, wherein the ratio of the aqueous phase in the composition is 45 to 78% by weight /O type emulsion composition <7> Further, the O/W/O type emulsion composition <8> according to any one of <1> to <6>, which contains (c) an organically modified clay mineral, and (d) cross-linking The O/W/O emulsion composition <9> according to any one of <1> to <7>, which contains a type methylpolysiloxane, and further contains (e) a diester of dimer acid and/or a diester of dimer diol The O/W/O emulsion composition <10> of any one of <1> to <8> O/W/O type containing (a) hydrogenated lecithin and (b) diglyceryl monooleate A method for producing an emulsified composition, wherein the surfactant, oil, and aqueous component containing (a) hydrogenated lecithin and (b) diglyceryl monooleate are mixed under heating to form an O/W emulsion. <11> A method for producing an O/W/O type emulsified composition, which comprises mixing the O/W emulsion and an oil agent to prepare an O/W/O emulsion after preparation <11> The O/W emulsion is The method for producing an O/W/O emulsion composition according to <10>, wherein the heating condition during preparation is 71 to 80°C.

All percentages referred to herein are by weight unless otherwise indicated.

According to the present invention, it is possible to improve the penetration of the stratum corneum of the drug contained in the O/W/O emulsified composition, and achieve both penetration feeling and stability over time.

(1) Hydrogenated lecithin as an essential component of the emulsified composition of the present invention The O/W/O type emulsified composition of the present invention contains (a) hydrogenated lecithin. (a) Hydrogenated lecithin is obtained by hydrogenating lecithin obtained from soybean or egg yolk to increase its stability, and those commonly used in the fields of cosmetics, pharmaceuticals and foods can be used. Its content can be appropriately set depending on the use of the composition, preferably 0.1 to 2% in the composition, more preferably 0.1 to 1%, 0.1 to 0.5% More preferred. If the content is less than 0.1%, it may not exert a sufficient effect on the stratum corneum permeability, and if the content exceeds 2%, it may precipitate.

(2) Diglyceryl Monooleate, an Essential Component of the Emulsified Composition of the Present Invention The O/W/O type emulsified composition of the present invention contains (b) diglyceryl monooleate. (b) Diglyceryl monooleate is a polyglycerin-based nonionic surfactant having an oleic acid residue, and those commonly used in the fields of cosmetics, pharmaceuticals and foods can be used. Its content can be appropriately set depending on the application of the composition, but is preferably 0.01 to 0.8%, more preferably 0.05 to 0.4%, more preferably 0.05 to 0.05% in the composition .2% is more preferred. If the content is less than 0.01%, a sufficient effect on stratum corneum permeability may not be exhibited, and if the content exceeds 0.8%, formation of an O/W emulsion becomes difficult (poor emulsification). Sometimes.

In addition, the O/W/O emulsion composition of the present invention contains (a) hydrogenated lecithin and (b) diglyceryl monooleate in the range of (a):(b) = 19:1 to 12:8. characterized by More preferably, it is 16:4 to 12:8. If the content exceeds this range, it may become difficult to form an O/W emulsion (defective emulsification).

The O/W/O emulsion composition of the present invention is characterized in that both (a) hydrogenated lecithin and (b) diglyceryl monooleate are present at the interface of the O/W emulsion. The presence of both (a) hydrogenated lecithin and (b) diglyceryl monooleate at the interface of the O/W emulsion further improves the penetration of the drug into the stratum corneum.

(3) O/W/O type emulsion composition of the present invention The emulsion composition of the present invention is characterized by being an O/W/O type emulsion composition. An O/W/O emulsion composition has a structure in which an aqueous phase is dispersed in an outer oil phase, and an inner oil phase is further dispersed in the aqueous phase. The composition ratio of the outer oil phase, aqueous phase, and inner oil phase constituting the O/W/O emulsion composition can be appropriately set depending on the use of the composition, but the ratio of the O/W emulsion to the composition is is preferably 65 to 80%, more preferably 68 to 80%, even more preferably 68 to 74%. If it is less than 65%, it may not exert sufficient effect on the feeling of penetration, and if it exceeds 80%, it may become difficult to form an O/W/O type emulsion composition (poor emulsification). The surfactant present at the interface between the inner oil phase and the water phase is included in the O/W emulsion, and the surfactant present at the interface between the water phase and the outer oil phase is not included in the O/W emulsion. do.

The proportion of the internal oil phase in the composition is preferably 2 to 20%, more preferably 2 to 10%, even more preferably 2 to 5%. If the content is less than 2%, a sufficient effect may not be exhibited for the firmness feeling, and if the content exceeds 20%, a sufficient effect may not be exhibited for the penetrating feeling. The surfactant present at the interface between the internal oil phase and the water phase is not included in the internal oil phase.

The proportion of the aqueous phase in the composition is preferably 45-78%, more preferably 58-78%, even more preferably 63-72%. If it is less than 45%, it may not exhibit a sufficient effect on the feeling of penetration, and if it exceeds 78%, it may become difficult to form an O/W/O type emulsion composition (poor emulsification). The surfactant present at the interface between the inner oil phase and the water phase is included in the water phase, and the surfactant present at the interface between the water phase and the outer oil phase is not included in the water phase.

The O/W/O emulsified composition of the present invention is preferably an external preparation for the skin because it can improve the penetration of the drug into the stratum corneum. Therefore, it is preferably a cosmetic.

(4) Organically Modified Clay Mineral, Preferred Component of the Present Invention The O/W/O emulsified composition of the present invention preferably further contains (c) an organically modified clay mineral. Here, the term "organic modification" refers to the formation of a strong or loose bond between a part of the clay mineral and a part of the organic compound through covalent or ionic bonds, and thereby making part or all of the properties of the organic compound Examples of such modification include a method of bonding a quaternary amino group with an anion moiety of a clay mineral, a method of bonding a carboxyl group with a cation moiety of a clay mineral, and the like. A particularly preferable example is a method of bonding a group to an anion portion of a clay mineral.

A compound having a quaternary amino group that modifies clay minerals is not particularly limited, but a compound called quaternium is exemplified. Quaternium is a low-molecular-weight substituted quaternary ammonium salt, preferably a cosmetic ingredient registered in the International Standard Cosmetic Ingredients (INCI). Furthermore, among quaternium compounds, the compound having a quaternary amino group that modifies the clay mineral is preferably a quaternium compound contained in conventional external preparations for skin. Preferred examples of quaternium compounds used in conventional external skin preparations include stearyltrimethylammonium chloride and dimethyldistearylammonium chloride. Stearyltrimethylammonium chloride, dimethyldistearylammonium chloride and the like are preferable because they can form a stable O/W/O emulsion composition together with clay minerals.

On the other hand, as the clay mineral modified with a compound having a quaternary amino group (unmodified clay mineral), any clay mineral contained in conventional external preparations for skin can be used without particular limitation. Clay minerals contained in conventional external preparations for skin preferably include smectite hectorite, bentonite and montmorillonite; kaolinite; illite; marine clay minerals (sea mud); desert rose clay minerals; Among these, bentonite, hectorite, montmorillonite and kaolinite are preferred. Among them, bentonite is preferable because it can form a stable O/W/O emulsion composition. Such organically modified clay minerals are already commercially available, and such commercial products can be purchased and used. Preferred commercially available products include, for example, "Bentone 38V" manufactured by Elementis Japan.

Its content can be appropriately set depending on the application of the composition, but is preferably 1 to 4%, more preferably 1 to 2%, and even more preferably 1.5 to 2% in the composition. If the content is less than 1%, it may be difficult to ensure stability over time.

(5) Crosslinked methylpolysiloxane, which is a preferred component of the present invention The O/W/O emulsion composition of the present invention preferably contains a crosslinked methylpolysiloxane. Crosslinked methylpolysiloxane can be produced by adding a crosslinking agent such as methyltrimethoxysiloxane when dimethoxydimethylsiloxane is polymerized to produce two-dimensional methylpolysiloxane. A (dimethicone/vinyl dimethicone) crosspolymer can also be used in which a crosslinked structure is constructed by copolymerizing dimethoxydimethylsiloxane and dimethoxymethylvinylsiloxane and then polymerizing vinyl groups. Methylpolysiloxane having such a crosslinked structure is already commercially available, and such commercial products can be purchased and used. Preferred commercially available products include, for example, "Silicone KSG-16" manufactured by Shin-Etsu Silicone Co., Ltd., and the like.

Its content can be appropriately set depending on the use of the composition, but is preferably 1 to 4%, more preferably 1 to 3%, and even more preferably 2 to 3% in the composition. If the content is outside this range, the effect on penetration may not be sufficient.
It should be noted that crosslinked methylpolysiloxane can be more effectively exerted on the permeation feeling when blended in the outermost oil phase, and more effective when blended only in the outermost phase.

(6) Diester of dimer acid and/or diester of dimer diol, which are preferred components of the present invention The O/W/O emulsion composition of the present invention contains a diester of dimer acid and/or a diester of dimer diol. is preferred. A diester of dimer acid can be obtained by esterifying dimer acid with various alcohols according to a conventional method. A diester of dimer diol can be obtained by reducing a dimer acid to form a dimer diol and esterifying it with a fatty acid. In addition, the ester of dimer acid and dimer diol can be included in the concepts of both the diester of dimer acid and the diester of dimer diol.

Diesters of dimer acid and diesters of dimer diol include, for example, di(phytosteryl/isostearyl/cetyl/stearyl/behenyl) dimer dilinoleate, di(isostearyl/phytosteryl) dimer dilinoleate, dimer dilinoleate Examples include linoleyl and hydrogenated dimer dilinoleyl dimer dilinoleate. Among them, it is particularly preferable to use di(phytosteryl/isostearyl/cetyl/stearyl/behenyl) dimer dilinoleate. A commercially available diester of dimer acid or a diester of dimer diol can also be used. Commercially available products contain a diester of dimer acid as a main component, and the content thereof is usually 70% by weight or more, preferably 90% by weight or more. Commercially available products include, for example, di(phytosteryl/isostearyl/cetyl/stearyl/behenyl) dimer dilinoleate "Prandool S" and "Prandool H" (Plandool-S, Plandool-H; Nippon Fine Chemical Co., Ltd.). ), hydrogenated dimer dilinoleic acid (isostearyl / phytosteryl) "LUSPLAN PI-DA" (LUSPLAN PI-DA; manufactured by Nippon Fine Chemical Co., Ltd.), hydrogenated dimer dilinoleyl dimer dilinoleate " LUSPLAN DD-DA5" (LUSPLAN DD-DA5; manufactured by Nippon Fine Chemical Co., Ltd.) and "RASPLAN DD-DA7" (LUSPLAN DD-DA7; manufactured by Nippon Fine Chemical Co., Ltd.), dimer dilinoleyl diisostearate (LUSPLAN DD-IS ; manufactured by Nippon Fine Chemical Co., Ltd.).

The O/W/O emulsified composition of the present invention may contain one of the diester of dimer acid and the diester of dimer diol alone, or may contain two or more of them in combination. may be The content thereof can be appropriately set depending on the use of the composition, but is preferably 0.5 to 3%, more preferably 0.5 to 2%, and even more preferably 0.5 to 1% in the composition. . If the content is less than 0.5%, a sufficient effect may not be exerted on the feeling of firmness, and if the content exceeds 3%, stickiness may occur.
The diester of dimer acid and the diester of dimer diol can be more effectively exerted on the firmness feeling when blended in the innermost oil phase, and more effectively when blended only in the innermost oil phase.

(7) Other components of the present invention In addition to the essential components and preferred components described above, the emulsified composition of the present invention may contain optional components commonly used in emulsified compositions. Such optional ingredients include, for example, macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, and hydrogenated coconut oil. Oil, hydrogenated oil, Japanese wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ibota wax, lanolin, reduced lanolin, hard lanolin, jojoba wax, waxes, liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, Petrolatum, hydrocarbons such as microcrystalline wax, higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, cetostearyl alcohol, etc., cetyl isooctanoate, isopropyl myristate, hexyl isostearate Decyl, diisopropyl adipate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glyceryl di-2-heptylundecanoate, glyceryl tri-2-ethylhexanoate, etc. Synthetic ester oils, chain polysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane and diphenylpolysiloxane, cyclic polysiloxanes such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexanesiloxane, amino-modified polysiloxane , polyether-modified polysiloxane, alkyl-modified polysiloxane, modified polysiloxane such as fluorine-modified polysiloxane, potassium lauryl sulfate, anionic surfactants such as alkyl sulfate triethanolamine ether, stearyltrimethylammonium chloride, benzalkonium chloride, Cationic surfactants such as laurylamine oxide, imidazoline amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine surfactants (alkylbetaine, amidobetaine, sulfobetaine, etc.), amphoteric surfactants such as acylmethyl taurine, sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glyceryl monostearate, etc.), propylene glycol fatty acid Esters (propylene monostearate recall, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitol fatty acid esters (POE-sorbit monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkylphenyl ethers ( POE nonylphenyl ether, etc.), pluronic types, POE/POP alkyl ethers (POE/POP 2-decyltetradecyl ether, etc.), tetronics, POE castor oil/hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil etc.), nonionic surfactants such as alkyl glucosides, (glycerin/oxybutylene) copolymer alkyl ethers, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene Polyhydric alcohols such as glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexanediol, 1,2-hexanediol, 1,2-octanediol, sodium pyrrolidonecarboxylate, lactic acid, lactic acid Moisturizing ingredients such as sodium, guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylhydroxypropylcellulose, chondroitin sulfate, dermatan sulfate, glycogen , heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hydroxyethyl guar gum, carboxymethyl guar gum, dextran, kerato sulfate, locust bean gum, succinoglucan, caronin acid, chitin, chitosan, carboxy Thickeners such as methyl chitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, alkyl-modified carboxyvinyl polymer, sodium polyacrylate, polyethylene glycol, bentonite, surface powders such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate, etc., the surface of which may be treated, Inorganic pigments such as red iron oxide, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine blue, Prussian blue, titanium oxide, zinc oxide, pearlescent agents such as mica titanium, fish phosphorus foil, bismuth oxychloride that may be surface-treated Red No. 202, Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204 and other organic pigments, polyethylene powder, polymethyl methacrylate, nylon powder, organic pigments such as organopolysiloxane elastomers, Powders, para-aminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 2-(2-hydroxy -5-t-octylphenyl)benzotriazole, UV absorbers such as UV absorbers such as 4-methoxy-4-t-butyldibenzoylmethane, lower alcohols such as ethanol and isopropanol, vitamin A or derivatives thereof, B vitamins such as vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or its derivatives, vitamin B12, vitamin B15 or its derivatives, α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E acetate vitamins such as vitamin E, vitamin D, vitamin H, pantothenic acid, pantethine, pyrroloquinoline quinone, antibacterial agents such as phenoxyethanol, anti-inflammatory agents such as glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof , ascorbic acid phosphate, ascorbic acid glucoside, tranexamic acid, arbutin, kojic acid, and other whitening agents.

The O/W/O type emulsified composition of the present invention can be produced by mixing and emulsifying the components of the inner oil phase, the water phase and the outer oil phase.

(8) Production method In the present invention, a surfactant containing (a) hydrogenated lecithin and (b) diglyceryl monooleate, an oil, and an aqueous component were mixed under heating to prepare an O/W emulsion. Later, the present invention also relates to a method for producing an O/W/O type emulsified composition, characterized by mixing the O/W emulsion and an oil agent to prepare an O/W/O emulsion. By adopting such a production method, it is possible to improve the penetration of the drug into the stratum corneum, and to achieve both a feeling of penetration and stability over time.

The present invention also relates to a method for producing an O/W/O emulsion composition, characterized in that the heating condition for preparing the O/W emulsion is 71 to 80°C. By adopting such a production method, it is possible to improve the penetration of the drug into the stratum corneum, and to achieve both a feeling of penetration and stability over time.

EXAMPLES The present invention will be described in more detail below with reference to Examples, but it goes without saying that the present invention is not limited to these Examples.

<Manufacturing example>
According to the formulation shown in Table 1, an O/W emulsion essential for the O/W/O emulsion composition of the present invention was produced. That is, after the components (a), (b), and (c) are heated to 75° C. and dissolved, (a) is gradually added to (b) while stirring, and then (c) is added. , and cooled to 30°C after homogenization to obtain an O/W emulsion of Production Example 1.
Comparative Production Example 1 was obtained by operating in the same manner. The numbers in the table represent % by weight.

<Preparation example>
According to the formulation shown in Table 1, Preparation Example 1 and Comparative Preparation Example 1 corresponding to Production Example 1 and Comparative Production Example 1 and containing a water-soluble fluorescent reagent were prepared. That is, after the components (a), (b), and (c) are heated to 75° C. and dissolved, (a) is gradually added to (b) while stirring, and then (c) is added. , and cooled to 30°C after homogenization to obtain an O/W emulsion of Preparation Example 1.
Comparative preparation example 1 was obtained by operating in the same manner. The numbers in the table represent % by weight.

<Test Example 1>
For Preparation Example 1 and Comparative Preparation Example 1, the stratum corneum permeability of the drug was measured by a transdermal permeability test using a Franz cell. LabcyteEPI-MODEL24 (Japan Tissue Engineering) was used as the three-dimensional cultured epidermis. A 30 mM aqueous solution of calcein sodium (manufactured by Wako Pure Chemical Industries) was used as a model labeled drug. The test procedure is shown below. The three-dimensional cultured epidermis was pre-incubated for 1 hour at 37°C and 5% _CO2 . After that, each sample was administered to the three-dimensional cultured epidermis at 100 μg/well. After 6 hours, 500 μL of the receiver solution of the three-dimensional cultured epidermal strain was collected, and fluorescence intensity was measured. From the obtained fluorescence intensity, the permeation amount of calcein sodium was calculated. Table 2 shows the results. From this result, it can be seen that the amount of penetration below the stratum corneum of the O / W emulsion containing (a) hydrogenated lecithin and (b) diglyceryl monooleate increased, and at the same time (a) hydrogenated lecithin and ( b) It was suggested that the penetration of the stratum corneum of the drug contained in the innermost oil phase and aqueous phase in the O/W/O emulsion composition containing diglyceryl monooleate is improved.

<Examples 1-12 and Comparative Example 1>
According to the formulation shown in Table 3, an O/W emulsion essential for the O/W/O emulsion composition of the present invention was produced. That is, after heating the components (a), (b), (c), and (d) to 75 ° C. and dissolving them, (a) is gradually added to (a) while stirring, and then ( c) was added and homogenized to obtain an O/W emulsion. This O/W emulsion was added to (d), homogenized, and then cooled to 30° C. to obtain an O/W/O emulsion composition of Example 1.
Examples 2 to 12 of the present invention and Comparative Example 1 were obtained in the same manner. The numbers in the table represent % by weight.

<Test Example 2>
Usability of Examples 1 to 12 and Comparative Example 1 was examined. Evaluation was made by 10 panelists, and scores were given according to the following evaluation criteria, and the average was taken. Table 3 shows the results. From this, it can be seen that the O/W/O emulsion composition of the present invention is excellent in usability. In addition, it is generally said that it is very difficult to achieve both penetration and firmness.

Evaluation criteria (feeling of penetration)
5: Penetrates very quickly.
4: Penetrates quickly.
3: Penetrates rather quickly.
2: Penetration is slightly slow.
1: Penetration is slow.

Evaluation criteria (tension)
5: There is a very firm feeling.
4: There is a firm feeling.
3: Slightly firm feeling.
2: There is a slightly firm feeling.
1: There is no firm feeling.

<Test Example 3>
The stability of Examples 1 to 12 and Comparative Example 1 over time at high temperatures was investigated. Specifically, the cosmetic was packed in a sample container, stored in a constant temperature box at 50° C., and observed after one month. Evaluation was made according to the following evaluation criteria. Table 3 shows the results. From this, it can be seen that the O/W/O emulsion composition of the present invention has excellent stability over time at high temperatures.

Evaluation criteria ⊚: No change.
◯: No change in appearance, but somewhat soft.
Δ: There is unevenness on the surface.
x: Bleeding and separation on the surface are observed.

INDUSTRIAL APPLICABILITY The present invention is a technology relating to O/W/O emulsion compositions, and can be applied to cosmetics, pharmaceuticals, foods, and the like.

Claims (11)

An O/W/O emulsion composition containing (a) hydrogenated lecithin and (b) diglyceryl monooleate ,
characterized in that the ratio of the O/W emulsion in the composition is 65 to 80% by weight,
An O/W/O emulsion composition containing cyclopentasiloxane in the outer oil phase . O according to claim 1, characterized by containing (a) hydrogenated lecithin and (b) diglyceryl monooleate in the range of (a):(b) = 19: 1 to 12: 8 /W/O type emulsion composition. 3. The O/W/O emulsion composition according to claim 1, wherein (a) hydrogenated lecithin and (b) diglyceryl monooleate are present at the interface between the internal oil phase and the aqueous phase. thing. 4. The O/W/O emulsion composition according to any one of claims 1 to 3 , wherein the internal oil phase accounts for 2 to 20% by weight of the composition. 5. The O/W/O emulsion composition according to any one of claims 1 to 4 , characterized in that the proportion of the aqueous phase in the composition is 45-78% by weight. 6. The O/W/O emulsion composition according to any one of claims 1 to 5 , further comprising (c) an organically modified clay mineral. 7. The O/W/O emulsion composition according to any one of claims 1 to 6 , further comprising (d) crosslinked methylpolysiloxane. 8. The O/W/O emulsion composition according to any one of claims 1 to 7 , further comprising (e) a diester of dimer acid and/or a diester of dimer diol. 9. The O/W/O emulsion composition according to claim 8, wherein the (e) is contained in the internal oil phase. A method for producing an O/W/O emulsion composition containing (a) hydrogenated lecithin and (b) diglyceryl monooleate, wherein the (a) hydrogenated lecithin and (b) diglyceryl monooleate After preparing an O / W emulsion by mixing a surfactant, an oil agent, and an aqueous component containing A method for producing an O/W/O emulsion composition, characterized by preparing 11. The method for producing an O/W/O emulsion composition according to claim 10, wherein the heating condition for preparing the O/W emulsion is 71 to 80°C.